• Neuralstem Inc., of Rockville, Md., said it started dosing in the second cohort of patients in its Phase Ib trial testing NSI-189 in major depressive disorder. The study is enrolling 24 patients, and the Phase Ib portion is expected to take about six months to complete. NSI-189 is a small molecule designed to stimulate new neuron growth in the hippocampus.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST